Related Experiment Videos
Kinetic studies of small molecule interactions with protein kinases using biosensor technology
Helena Nordin1, Maria Jungnelius, Robert Karlsson
1Department of Biochemistry and Chemistry, Biacore AB, Rapsgatan 7, SE-754 50 Uppsala, Sweden.
Analytical Biochemistry
|April 21, 2005
Summary
This study introduces a new biosensor method for studying kinase inhibitors. The surface plasmon resonance (SPR) technique provides detailed kinetic data for drug discovery, improving understanding of inhibitor interactions.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Protein kinases are crucial drug targets, yet studying kinase inhibitors with surface plasmon resonance (SPR) is challenging due to assay limitations.
- Developing robust assays is essential for advancing kinase inhibitor research and development.
Purpose of the Study:
- To present a general biosensor-based methodology for studying small molecule interactions with eight different serine/threonine and tyrosine kinases.
- To establish key factors for successful kinase-SPR assays, including immobilization conditions and buffer composition.
Main Methods:
- Utilized biosensor technology for direct binding studies of small molecules to immobilized kinases.
- Performed kinase activity assays to validate inhibitory effects.
- Conducted detailed kinetic analyses to determine inhibitor binding and dissociation rates.
- Employed competition assays with ATP to identify competitive inhibitors.
Main Results:
- Identified mild immobilization conditions and a specific assay buffer as critical for assay success.
- Successfully applied the methodology to eight diverse kinases.
- Obtained detailed kinetic data, resolving affinity into binding and dissociation rates.
Conclusions:
- The developed SPR methodology offers a powerful tool for in-depth analysis of kinase inhibitor interactions.
- This approach provides crucial insights into inhibitor structure-function relationships, aiding the development of effective kinase inhibitors.